Ipilimumab, nivolumab and tocilizumab as first-line therapy for advanced melanoma.

被引：8
|
作者：
Mehmi, Inderjit
Hamid, Omid
Hodi, F. Stephen
Vassalo, Melinda
Malatyali, Saundra
Krishnarajapet, Swathi
O'Donnell, Nan
Castrence, Angeli
Lim, Eunice
Gormley, Jill
Weber, Jeffrey S.
机构：
[1] Angeles Clin & Res Inst, Los Angeles, CA USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] NYU Langone Hlth, Laura & Issac Perlmutter Canc Ctr, New York, NY USA
[4] NYU Langone, Perlmutter Canc Ctr, New York, NY USA
[5] Perlmutter Canc Ctr, New York, NY USA
[6] NYU Langone, New York, NY USA
[7] Angeles Clin & Res Inst Inc, Los Angeles, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS9589
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9589
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC
    Li, Jiahao
    Zhang, Tiantian
    Xu, Yongmei
    Lu, Peiyao
    Zhu, Jiaxin
    Liang, Wenhua
    Jiang, Jie
    [J]. IMMUNOTHERAPY, 2020, 12 (14) : 1067 - 1075
  • [42] Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma
    Weber, J. S.
    Muramatsu, T.
    Hamid, O.
    Mehnert, J.
    Hodi, F. S.
    Krishnarajapet, S.
    Malatyali, S.
    Buchbinder, E.
    Goldberg, J.
    Sullivan, R.
    Faries, M.
    Mehmi, I.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S869 - S869
  • [43] Characterization of complete responders to combination nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with advanced, unresectable melanoma.
    Warner, Allison Betof
    Shoushtari, Alexander Noor
    Houghton, Sean
    Panageas, Katherine
    Chapman, Paul B.
    Wolchok, Jedd D.
    Postow, Michael A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] Ipilimumab with anti PD-1 (nivovlumab or pembrolizumab) after progression on first line anti-PD-1 therapy for advanced melanoma.
    Mehmi, Inderjit
    Hill, Jordan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] Trial in progress: clinical trial of nivolumab combined with ipilimumab followed by nivolumab monotherapy as first-line therapy of patients with stage III (unresectable) or stage IV melanoma: CheckMate 401
    Dummer, R.
    Gutzmer, R.
    Corrie, P.
    Millward, M.
    Murzhenko, A.
    Maio, M.
    [J]. MELANOMA RESEARCH, 2016, 26 : E43 - E43
  • [46] Updated analysis of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma
    Takahashi, Akira
    Namikawa, Kenjiro
    Ogata, Dai
    Jinnai, Shunichi
    Nakano, Eiji
    Yamazaki, Naoya
    [J]. JOURNAL OF DERMATOLOGY, 2023, 50 (04): : 525 - 535
  • [47] Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan
    Xiuting Mo
    Kensuke Moriwaki
    Kosuke Morimoto
    Kojiro Shimozuma
    [J]. Clinical Drug Investigation, 2022, 42 : 599 - 609
  • [48] Cost-Effectiveness of First-Line Nivolumab Plus Ipilimumab Combination Therapy in Advanced Non-Small-Cell Lung Cancer in Japan
    Mo, Xiuting
    Moriwaki, Kensuke
    Morimoto, Kosuke
    Shimozuma, Kojiro
    [J]. CLINICAL DRUG INVESTIGATION, 2022, 42 (07) : 599 - 609
  • [49] Milestones in the Treatment of malignant Melanoma Nivolumab in the Adjuvant and as a Combination Therapy with Ipilimumab in Patients with advanced Melanoma
    Sankawa, Yuri
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (7-8) : 414 - 415
  • [50] Cost-effectiveness of nivolumab plus ipilimumab versus chemotherapy as first-line therapy in advanced non-small cell lung cancer
    Shu, Yamin
    Ding, Yiling
    Li, Feie
    Zhang, Qilin
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 114
12345